Precision medicine using monoclonal antibodies in cancer therapy

Muhammad Taher

doi:10.31436/jop.v4i1.271

Authors

Muhammad Taher Kulliyyah of Pharmacy, International Islamic University Malaysia, 25200, Kuantan, Pahang, Malaysia https://orcid.org/0000-0002-1463-3090

DOI:

https://doi.org/10.31436/jop.v4i1.271

Abstract

Nil

References

Ebrahimi, S. B., & Samanta, D. (2023). Engineering protein-based therapeutics through structural and chemical design. Nature Communications, 14(1), 2411. https://doi.org/10.1038/s41467-023-38039-x

Guimaraes Koch, S. S., Thorpe, R., Kawasaki, N., Lefranc, M.-P., Malan, S., Martin, A. C. R., Mignot, G., Plückthun, A., Rizzi, M., Shubat, S., Weisser, K., & Balocco, R. (2022). International nonproprietary names for monoclonal antibodies: An evolving nomenclature system. mAbs, 14(1), 2075078. https://doi.org/10.1080/19420862.2022.2075078

Hauser, S. L., Kappos, L., Bar-Or, A., Wiendl, H., Paling, D., Williams, M., Gold, R., Chan, A., Milo, R., Das Gupta, A., Karlsson, G., Sullivan, R., Graham, G., Merschhemke, M., Häring, D. A., & Vermersch, P. (2023). The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment. Neurology and Therapy, 12(5), 1491–1515. https://doi.org/10.1007/s40120-023-00518-0

Köhler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495–497. https://doi.org/10.1038/256495a0

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660

Zahavi, D., & Weiner, L. (2020). Monoclonal Antibodies in Cancer Therapy. Antibodies, 9(3), 34. https://doi.org/10.3390/antib9030034